Evidence map›Paper›PMID 42723801›Full record

ArticleTranslational lung cancer research2026

Highest mediastinal lymph node metastasis was not an independent prognostic factor in pathological stage N2 non-small cell lung cancer.

Mu-Zi Yang, Jing-Sheng Cai, Zeng-Hao Chang, Xue Hou, Hao-Xian Yang

Abstract read
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mu-Zi Yang *Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jing-Sheng Cai *Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zeng-Hao ChangDepartment of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xue HouState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Hao-Xian YangDepartment of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0002-1940-3657

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Based on the definition of R stage proposed by the International Association for the Study of Lung Cancer (IASLC), non-small cell lung cancer (NSCLC) patients with highest mediastinal lymph node (HMLN) metastasis should be classified as uncertain resection. However, previous studies about HMLN metastasis had different voices, and the prognostic significance of HMLN metastasis is still controversial. This study aimed to investigate the impact of HMLN metastasis on overall survival (OS) and disease-free survival (DFS) in patients with pathological stage N2 (pN2) NSCLC. Methods: Patients with pN2 NSCLC treated between 2001 and 2014 were retrospectively included, while those with R1/R2 resection or insufficient lymph node dissection were excluded. Patients were categorized into two groups: those with HMLN metastasis (HMLN Results: The study included 332 patients, of whom 142 (42.8%) had HMLN metastasis. After PSM, 90 matched pairs were generated. Patients in the HMLN Conclusions: HMLN metastasis was not an independent prognostic factor for OS or DFS in patients with stage N2 NSCLC. Patients with HMLN metastasis were more likely to have pN2b disease, which may account for the poorer survival observed in this group.

Indexed as

Highest mediastinal lymph node metastasis (HMLN metastasis)non-small cell lung cancer (NSCLC)survival

Identifiers

PMID42723801
PMCPMC13557878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.